Safe­ty is­sues force No­vo Nordisk to shut­ter PhI­II he­mo­phil­ia tri­als

Five months af­ter rolling out proof-of-con­cept da­ta on their an­ti-tis­sue fac­tor path­way in­hibitor con­cizum­ab, No­vo Nordisk abrupt­ly shut down a trio of ad­vanced clin­i­cal tri­als in the wake of se­ri­ous safe­ty is­sues.

The phar­ma com­pa­ny slammed the brakes on the three tri­als in­volv­ing he­mo­phil­ia A and B pa­tients — 2 Phase II­Is and 1 Phase II — re­gard­less of in­hibitor sta­tus af­ter 3 pa­tients in the piv­otal pro­gram ex­pe­ri­enced non-fa­tal throm­bot­ic events, or blood clots.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.